Colon-directed synbiotic nanocarriers offer a promising approach for Alzheimer's disease management by targeting the gut–brain axis. This strategy enables targeted delivery of synbiotics to the colon, promoting gut microbiota balance, reducing neuroinflammation, and potentially slowing disease progression. Further preclinical and clinical studies are needed to establish its safety, efficacy, and therapeutic potential.